Barzolvolimab - KIT Inhibitor Program:...Additional Indications (GlobeNewswire) - Nov 10, 2025 - "(i) Enrollment continues in the Phase 2 study in prurigo nodularis (PN)....Initial data from this study are expected to be presented in 2H 2026; (ii) Enrollment is ongoing in the Phase 2 study in atopic dermatitis (AD)....Initial data from this study are expected to be presented in 2H 2026."
Enrollment status • P2 data • Atopic Dermatitis • Prurigo Nodularis
|